Novartis India delivered exceptional performance with shares surging 8.82% to hit its fresh 52-week high of ₹2,383 during Wednesday's trading session. According to market reports, the stock opened at ₹2,252 and reached a high of ₹2,383 before closing at ₹2,380.90, representing a day change of ₹192.90 from the previous close of ₹2,188. This dramatic performance has been particularly noteworthy as it comes during a period of weak overall stock market sentiment, highlighting the stock's resilience and strong investor interest. The stock's achievement of its 52-week high of ₹2,383 represents a significant technical and psychological milestone for investors, with the benchmark Sensex declining 813 points to close at 74,764 during the same session, making these gains even more impressive.
The stock's recent performance is supported by strong financial fundamentals, with Novartis India reporting recent revenue of ₹1,038.1 crore and net profit of ₹322.1 crore for June 2026. The company maintains impressive profitability ratios with ROE of 13.19% and ROCE of 17.15%, positioning it above sector benchmarks. However, the stock trades at a premium valuation with P/E ratio of 55.26x, which is significantly above the benchmark median of 23.84x, representing a difference of +131.8%. The company's market capitalisation stands at ₹5,402.35 crore, placing it above the sector median market cap in the benchmark set. EPS is reported at ₹39.6 with book value per share of ₹344.28.
The stock's performance has been accompanied by notable trading activity, with turnover standing at ₹5.37 crore during the session. The spurt in volume that accompanied the price movement suggests heightened investor interest and active participation in the stock's rally. This increased trading activity typically indicates strong market sentiment and potential institutional or retail investor interest in the security, supporting the stock's ability to maintain its upward trajectory and reach new yearly highs. The trading activity occurred despite broader market weakness, highlighting the stock's relative strength and investor confidence.
According to latest Univest data, Novartis India compares favorably against industry peers with P/E of 55.26x versus peer median of 41.61x, ROE of 13.19% versus peer median of 15.07%, and ROCE of 17.15% versus peer median of 17.18%. The company is classified under the Trading sector and Trading industry, with recent revenue and net profit figures providing context for the stock's valuation and performance. The stock's ability to reach new yearly highs despite trading at premium valuations suggests strong underlying fundamentals and investor confidence in the company's growth prospects, particularly notable given the challenging market conditions that saw the BSE 150 Midcap index underperform.
